Amid the rising number of deaths from COVID-19, political leadership, health systems and scientific prowess is being tested locally and internationally. The pandemic provides an opportunity for innovation and new scientific discoveries. For example, the emergence of cases in Africa inspire African-based studies to tap into the diverse genetic background of Africans for important clues in the identification of biomarkers of coronavirus infection.
However, for global scientific solutions to come from Africa a number of prerequisites will need to be met.
The past two decades have been characterised by efforts to reduce the global burden of disease by providing universal access to healthcare for under-served and vulnerable populations. There have been parallel efforts to strengthen science, skills and infrastructure in Africa. The aim has been to support quality research and human capacity development working in research units and centres of excellence dotted across Africa.
But a response to a fast-emerging, highly infectious agent like COVID-19 demands a whole lot more. It requires strong collaboration, the use of new technologies and above all, fast-tracking of research.
Read more: What we've learnt from building Africa's biggest genome library
There has never been a more compelling time for African scientists to work together towards a common goal. An integrated approach is all the more imperative because any country that is left behind could be the next source of infection.
A crisis like COVID-19 demands that professional barriers be broken. This would facilitate a united approach by clinicians, scientists (both life and human sciences), biomedical engineers and public health specialists. Practically, this would entail assembling teams that work together, in the first instance, towards disaster management. In the second it would involve teams working on solutions that take into account the special circumstances of Africa – and each country.
These would be focused on quickly learning what has worked and not worked in the parts of the world that were affected first, and providing innovative ways forward for African countries. The size of Africa's economy and the connectedness of its populations demands that Africa's response be unified.
Collaboration is needed on another front too: technology.
The spread of the pandemic has resulted in an urgent need for a range of medical supplies. These range from personal protective equipment – face shields, surgical masks, diagnostic swabs, ventilator components and reusable N95 respirators. There is currently an international shortage of N95 respirators as well as ventilators. African countries can't procure these. They need to create their own.
Read more: Coronavirus: inside story of how Mercedes F1 and academics fast-tracked life saving breathing aid
The pandemic presents a good opportunity to use new technologies. For example, with the advancement of 3D printing technologies, these critical supplies could be made on-site as required. These technologies could be used to replicate protective personal equipment. Several universities in South Africa have started using 3D printing to make masks. Delicate choices must be made between the most advanced technologies and an appropriate technology that can work on the ground and be accomplished with the limitations in the supply chains due to global lockdowns.
In addition, technologies such as imaging , proteomics , metabolomics and genomics need to be applied to map the disease progression and its pathway and to conduct research on Africans in order to identify novel markers for vaccine or drug development.
There is therefore an urgent need for national regulatory bodies to develop and deploy dedicated fast-tracking mechanisms to support these kind of technologies.
Important questions for innovation and research include:
- understanding factors that facilitate infection with the coronavirus,
- the life-cycle of the virus once in the human body (use of imaging),
- the response of the host when invaded by the coronavirus in terms of genes expressed (transcriptomics),
- the differences in proteins expressed when comparing infected patients and the uninfected (proteomics), and
- the changes in the metabolites in the presence of the coronavirus (metabolomics).
As a continent, and as governments, teams comprising experts from these different fields should be in a state of readiness so that they can be easily activated. And governments should be setting up laboratories that can spring into action when required.
This crisis also presents an opportunity to access huge amounts of data from patients infected with COVID-19. These patients can participate in trials or their biological samples could be used in studies to advance science and medicine, and even to prepare for future pandemics.
Now more than ever, a strong motivation has been made for the need to increase research funding to strengthen responses by African scientists.
And research should be fast-tracked. Some changes should be made to facilitate this. One such change is that institutional and national ethics review boards should be allowed to waive some of the requirements for informed consent in very particular instances. Here we are thinking specifically about the use of samples with de-identified data, where there is no link to patient identity and when the research is of public health importance.
On top of this, strategic funds should be made available to support research that's critical to countries and the continent.
Beyond COVID-19, collective efforts can also help the continent address other critical health challenges. New disciplines have emerged that have forced medical professionals to break barriers and to stop working in silos. Examples include global health, global surgery and frugal science . These disciplines are forcing us to improve health outcomes.
In the current time of this COVID-19 crisis, the opportunity to tackle the pandemic through science and innovation should not be missed.
Salome Maswime receives funding from the South African Medical Research Council, and is the President of the South African Clinician Scientist's Society and a Next Einstein Forum fellow.
Collet Dandara receives funding from the Medical Research Council of South Africa (SAMRC), the National Research Foundation (NRF) South Africa and the University of Cape Town
Sudesh Sivarasu receives funding from the Medical Research Council of South Africa (SAMRC), the National Research Foundation (NRF) South Africa, and the University of Cape Town
By Salome Maswime, Head of Global Surgery, Obstetrician and Gynaecologist, University of Cape Town And
Collet Dandara, Professor, Division of Human Genetics, Department of Pathology,, University of Cape Town And
Sudesh Sivarasu, Associate Professor in Biomedical Engineering, Head of Medical Devices Lab, University of Cape Town